Cholesterol still matters after age 75, but not in the straightforward way it matters at 50. The relationship between cholesterol levels and health outcomes shifts as you age, and the benefit of treating high cholesterol depends heavily on whether you already have heart disease. For people over 75 with no history of heart attack or stroke, the evidence for lowering cholesterol is surprisingly thin. For those who do have established cardiovascular disease, the case for treatment remains strong.
Why the Answer Changes With Age
In younger adults, high LDL cholesterol is a reliable predictor of future heart attacks and strokes. The higher it goes, the greater the risk. But after 75, that link weakens considerably. A large population-based study found that the association between high non-HDL cholesterol (a broader measure that captures more harmful particles than LDL alone) and cardiovascular death was strongest in adults under 50 and weakest in adults 70 and older.
Even more striking, very low cholesterol levels appear to carry their own risks in older adults. Research consistently shows a U-shaped curve: both very high and very low LDL levels are associated with increased mortality. In adults over 70, having non-HDL cholesterol below 100 mg/dL was linked to a 56% higher risk of cardiovascular death compared to moderate levels. The lowest overall mortality risk corresponded to non-HDL cholesterol levels around 131 to 160 mg/dL, a range that would prompt concern in a younger person.
This doesn’t mean high cholesterol is protective in old age. It means the picture is more complicated. Cholesterol levels in older adults reflect overall health status in ways they don’t in younger people. Very low cholesterol can signal malnutrition, chronic inflammation, or underlying illness rather than cardiovascular fitness.
With Heart Disease: Treatment Still Helps
If you’ve already had a heart attack, stroke, or been diagnosed with coronary artery disease, cholesterol-lowering medication continues to provide meaningful protection after 75. A major analysis of older adults found that for every 1 mmol/L reduction in LDL cholesterol, the risk of major cardiovascular events dropped by 15% in people with existing vascular disease. That’s a clinically significant benefit that holds up in the over-75 population.
This is called secondary prevention, meaning you’re preventing a second event rather than a first one. The evidence here is clear enough that most guidelines recommend continuing statin therapy for older adults who are already on it for established heart disease, unless side effects or other health issues make it a poor fit.
Without Heart Disease: Much Less Certain
For older adults who have never had a cardiovascular event, the picture looks very different. This is primary prevention, and the data for people over 75 is limited. When researchers analyzed outcomes specifically in older adults without prior vascular disease, statin therapy did not produce a statistically significant reduction in major cardiovascular events.
The 2018 American Heart Association and American College of Cardiology cholesterol guidelines reflect this uncertainty. Starting a statin for primary prevention in adults over 75 receives only a Class IIb recommendation, the weakest positive rating, meaning it “may be reasonable” rather than clearly beneficial. The European Society of Cardiology guidelines are similarly cautious, giving statins for primary prevention a Class IIb recommendation for patients over 70. The U.S. Preventive Services Task Force has acknowledged that there simply isn’t enough data to assess the benefits and harms of starting statins in people 76 and older.
Time to Benefit Matters
One of the most practical considerations for cholesterol treatment after 75 is how long it takes for a statin to deliver a measurable benefit. A meta-analysis published in JAMA Internal Medicine estimated that treating 100 adults without cardiovascular disease for 2.5 years would prevent one major cardiovascular event in one of those adults. That study covered adults aged 50 to 75, and the researchers concluded that statins for primary prevention make sense only if life expectancy is at least 2.5 years.
For many healthy 75-year-olds, 2.5 years is well within reach. But for someone who is frail, managing multiple serious health conditions, or in declining health, the window may be too narrow for the medication to do any good. This is why guidelines increasingly emphasize individual assessment over blanket recommendations for this age group.
Side Effects Hit Harder in Older Adults
Statins are generally well-tolerated, but the risk of side effects increases with age. Muscle pain and weakness are the most common complaints, and they can be particularly disruptive for older adults whose mobility and independence are already fragile. A fall caused by muscle weakness can have far more serious consequences at 80 than at 60.
Cognitive concerns also come up frequently. A survey of statin users found that up to 75% reported some form of cognitive side effect. While large clinical trials have not confirmed that statins cause dementia, the worry is persistent enough that it factors into many patients’ decisions. A major ongoing trial called STAREE, which enrolled nearly 10,000 healthy adults aged 70 and older, is specifically designed to measure whether daily statin therapy extends disability-free life, including freedom from dementia. Results are expected in late 2025 and could reshape how doctors approach this question.
Older adults also tend to take more medications, and each additional drug increases the chance of harmful interactions. The more pills someone takes, the harder it becomes to tell which one is causing a new symptom.
How Doctors Should Make the Call
Current best practice treats cholesterol management after 75 as an individualized decision rather than a checkbox. The factors that matter most include whether you have existing heart disease, your overall functional status, how many other medications you take, and your realistic life expectancy.
Geriatric assessment tools like the Clinical Frailty Scale and prognosis calculators can help frame the conversation. A robust, active 78-year-old with high cholesterol and a strong family history of heart disease is a very different patient from a frail 78-year-old with diabetes, kidney disease, and limited mobility, even if their cholesterol numbers are identical.
For people already taking a statin, the question of whether to stop is just as important as whether to start. Guidelines suggest that for adults 75 and older, doctors should periodically reassess whether continuing therapy still makes sense given the person’s current health trajectory. Deprescribing, the deliberate and supervised process of stopping medications that are no longer beneficial, is increasingly recognized as good medical care rather than giving up.
Calcium Scoring as a Tiebreaker
When the decision to start a statin is genuinely uncertain, a coronary artery calcium (CAC) scan can help. This is a quick, low-radiation CT scan that measures the amount of calcified plaque in your heart’s arteries. The 2018 AHA/ACC guidelines specifically support using CAC scoring to help decide on statin therapy for patients over 75. A score of zero, meaning no detectable calcified plaque, can reasonably tip the scales toward skipping or stopping statin therapy for primary prevention in adults aged 76 to 80. A high score suggests real atherosclerotic burden that might benefit from treatment regardless of age.
The Bottom Line on Cholesterol After 75
Cholesterol doesn’t stop mattering at 75, but what counts as a healthy level and whether treating it helps both depend on context. If you have established heart disease, managing cholesterol continues to reduce your risk of another event. If you don’t, the benefits of cholesterol-lowering medication are unproven in your age group, and the decision should weigh your overall health, your other medications, your functional independence, and how many healthy years you’re likely to have ahead. The most important number isn’t always the one on your lab report.